BioVie has postponed plans for an initial public offering (IPO) valued at as much as $15 million, as reported NASDAQ Tuesday.
In the IPO, the company planned to offer 1.3 million shares at $11.44 per share.
To read more NewsPoints articles, click here.
About FirstWord Pharma | Refer a Colleague | Upgrade Your FirstWord Pharma | Contact FirstWord Pharma | FirstWord Reports
Advertise with FirstWord Pharma | Industry Partner Showcase
All Contents Copyright © 2019 Doctor's Guide Publishing Limited. All Rights Reserved.
Terms of Use | Privacy Policy